News
 
Pantaloon Retail Q2 net profit at Rs56.40 mn
India Infoline News Service/10:11,Feb 11, 2012
Total Income has increased from Rs. 10279.90 mn for the quarter ended December 31, 2010 to Rs. 11114.80 mn for the quarter ended December 31, 2011.
list India Infoline Weekly Newsletter - February 10, 2012
list This Valentine’s Day go crazy in love with ayesha’s accessories
list Shoppers Stop opens 50th store: reports
list Mother Dairy’s popular range of Ice Creams now in Bangalore

Calendar

Feb-2012
M T W T F S S
13 14 15 16 17 18 19
Economic Events
list QV House Prices (YoY)
list Food Prices (MoM)
Results
list CESC | Cipla | Ambuja Cem. | Castrol India
IPO
listNo IPO today
 

US nod for a generic drug lifts Ranbaxy Laboratories

Capital Market / 14:23 , Nov 20, 2009

Ranbaxy Laboratories rose 0.64% to Rs 419.95 at 14:23 IST on BSE, after the company received US Food & Drug Administration approval for Acetaminophen tablets in 650 miligram strengh for over the counter sales.

Meanwhile, the BSE Sensex was up 165.90 points, or 0.98%, to 16,955.40.

On BSE, 2.22 lakh shares were traded in the counter as against an average daily volume of 5.31 lakh shares in the past one quarter.

The stock had hit a high of Rs 421.80 and a low of Rs 412 so far during the day.

The company's equity capital is Rs 210.21 crore. Face value per share is Rs 5.

The current price of Rs 419.95 discounts the company's Q3 September 2009 annualized EPS of Rs 17.17, by a PE multiple of 24.46.

Acetaminophen is the generic version of McNeil Cons' Tylenol.

Ranbaxy Laboratories reported net profit of Rs 186.08 crore in Q3 September 2009 as compared to net loss of Rs 352.93 crore in Q3 September 2008. Net sales rose 3.8% to Rs 1189.60 crore in Q3 September 2009 over Q3 September 2008.

Ranbaxy Laboratories manufactures and markets, generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active pharmaceuticals and intermediates.

 



Rate This Article Rate 1 Rate 2 Rate 3 Rate 4 Rate 5
Average rating : 3.0